A four-year phase 2 clinical trial demonstrated that a peanut allergy treatment called sublingual immunotherapy, or SLIT, is effective and safe, while offering durable desensitization to peanuts in peanut-allergic children. SLIT is a treatment using a tiny amount of peanut protein that is the equivalent of only 1/75th of a peanut kernel. It is taken under the tongue, where it is absorbed into the body. The research shows that a 4 mg dose of peanut SLIT provides strong desensitization that would be expected to protect against accidental exposures to peanut in the majority of children. …The current trial was designed...